ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX): Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, today announced revenues and earnings for the first quarter ended March 31, 2008. Net revenues for the first quarter of 2008 increased 22% to $100.4 million from $82.3 million in the first quarter of 2007. Diluted earnings per share (EPS) for the first quarter of 2008 were $0.32 (inclusive of a non-cash impairment charge totaling $0.03 per share) compared with $0.36 for the first quarter of 2007. This non-cash impairment charge is related to the Company’s equity investment in Plethora Solutions, Ltd. Earnings before interest, taxes, depreciation and amortization, non-cash impairment and stock compensation expense (EBITDAS, a non-GAAP measure) were $30.9 million in the first quarter of 2008 compared with $28.6 million in the first quarter of 2007. Cash flow per share, also a non-GAAP measure, was $0.56 for the first quarter of 2008 compared with $0.54 for the first quarter of 2007.
